BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Del Bello A, Congy-Jolivet N, Danjoux M, Muscari F, Lavayssière L, Esposito L, Hebral AL, Bellière J, Kamar N. High tacrolimus intra-patient variability is associated with graft rejection, and de novo donor-specific antibodies occurrence after liver transplantation. World J Gastroenterol 2018; 24(16): 1795-1802 [PMID: 29713132 DOI: 10.3748/wjg.v24.i16.1795] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 27] [Article Influence: 9.3] [Reference Citation Analysis]
Number Citing Articles
1 Ko H, Kim HK, Chung C, Han A, Min SK, Ha J, Min S. Association between medication adherence and intrapatient variability in tacrolimus concentration among stable kidney transplant recipients. Sci Rep 2021;11:5397. [PMID: 33686160 DOI: 10.1038/s41598-021-84868-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 van Gelder T. A new method to calculate intra-patient variability in tacrolimus concentrations. Br J Clin Pharmacol 2021. [PMID: 33948976 DOI: 10.1111/bcp.14865] [Reference Citation Analysis]
3 Vionnet J, Sempoux C, Pascual M, Sánchez-fueyo A, Colmenero J. Donor-specific antibodies in liver transplantation. Gastroenterología y Hepatología 2020;43:34-45. [DOI: 10.1016/j.gastrohep.2019.09.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
4 Wang R, Wang W, Ma K, Duan X, Wang F, Huang M, Zhang W, Liang T. Variation in Tacrolimus Trough Concentrations in Liver Transplant Patients Undergoing Endoscopic Retrograde Cholangiopancreatography: A Retrospective, Observational Study. Front Pharmacol 2020;11:1252. [PMID: 32973503 DOI: 10.3389/fphar.2020.01252] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Potruch A, Khoury ST, Ilan Y. The role of chronobiology in drug-resistance epilepsy: The potential use of a variability and chronotherapy-based individualized platform for improving the response to anti-seizure drugs. Seizure 2020;80:201-11. [DOI: 10.1016/j.seizure.2020.06.032] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
6 Schumacher L, Leino AD, Park JM. Tacrolimus intrapatient variability in solid organ transplantation: A multiorgan perspective. Pharmacotherapy 2021;41:103-18. [PMID: 33131078 DOI: 10.1002/phar.2480] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
7 Shemesh E. Using Medication Level Variability to Predict Posttransplant Risk. Liver Transpl 2021;27:936-7. [PMID: 33576115 DOI: 10.1002/lt.26012] [Reference Citation Analysis]
8 Herblum J, Dacouris N, Huang M, Zaltzman J, Prasad GVR, Nash M, Chen L. Retrospective Analysis of Tacrolimus Intrapatient Variability as a Measure of Medication Adherence. Can J Kidney Health Dis 2021;8:20543581211021742. [PMID: 34188946 DOI: 10.1177/20543581211021742] [Reference Citation Analysis]
9 Udomkarnjananun S, Francke MI, De Winter BCM, Mulder MB, Baan CC, Metselaar HJ, den Hoed CM, Hesselink DA. Therapeutic drug monitoring of immunosuppressive drugs in hepatology and gastroenterology. Best Pract Res Clin Gastroenterol 2021;54-55:101756. [PMID: 34874840 DOI: 10.1016/j.bpg.2021.101756] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Süsal C, Döhler B. Late intra‐patient tacrolimus trough level variability as a major problem in kidney transplantation: A Collaborative Transplant Study Report. Am J Transplant 2019;19:2805-13. [DOI: 10.1111/ajt.15346] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
11 Brunet M, van Gelder T, Åsberg A, Haufroid V, Hesselink DA, Langman L, Lemaitre F, Marquet P, Seger C, Shipkova M, Vinks A, Wallemacq P, Wieland E, Woillard JB, Barten MJ, Budde K, Colom H, Dieterlen M, Elens L, Johnson-davis KL, Kunicki PK, Macphee I, Masuda S, Mathew BS, Millán O, Mizuno T, Moes DAR, Monchaud C, Noceti O, Pawinski T, Picard N, van Schaik R, Sommerer C, Vethe NT, de Winter B, Christians U, Bergan S. Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. Therapeutic Drug Monitoring 2019;41:261-307. [DOI: 10.1097/ftd.0000000000000640] [Cited by in Crossref: 131] [Cited by in F6Publishing: 46] [Article Influence: 43.7] [Reference Citation Analysis]
12 Leino AD, Pai MP. Maintenance Immunosuppression in Solid Organ Transplantation: Integrating Novel Pharmacodynamic Biomarkers to Inform Calcineurin Inhibitor Dose Selection. Clin Pharmacokinet 2020;59:1317-34. [PMID: 32720300 DOI: 10.1007/s40262-020-00923-w] [Reference Citation Analysis]
13 Choi D, Thaker S, West-Thielke P, Elmasri A, Chan C. Evaluating the conversion to extended-release tacrolimus from immediate-release tacrolimus in liver transplant recipients. Eur J Gastroenterol Hepatol 2021;33:1124-8. [PMID: 34213506 DOI: 10.1097/MEG.0000000000002172] [Reference Citation Analysis]
14 Thongprayoon C, Hansrivijit P, Kovvuru K, Kanduri SR, Bathini T, Pivovarova A, Smith JR, Cheungpasitporn W. Impacts of High Intra- and Inter-Individual Variability in Tacrolimus Pharmacokinetics and Fast Tacrolimus Metabolism on Outcomes of Solid Organ Transplant Recipients. J Clin Med 2020;9:E2193. [PMID: 32664531 DOI: 10.3390/jcm9072193] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
15 Li Y, Yan L, Li Y, Wan Z, Bai Y, Wang X, Hu S, Wu X, Yang C, Fan J, Xu H, Wang L, Shi Y. Development and validation of routine clinical laboratory data derived marker-based nomograms for the prediction of 5-year graft survival in kidney transplant recipients. Aging (Albany NY) 2021;13:9927-47. [PMID: 33795527 DOI: 10.18632/aging.202748] [Reference Citation Analysis]
16 Nnani DU, Campbell A, Ajaimy M, Saeed O, Patel SR, Ahmed S, Graham JA, Jorde UP. Effect of glecaprevir/pibrentasvir on weight-adjusted tacrolimus trough/dose ratios in heart and kidney transplant recipients. Transpl Infect Dis 2021;23:e13716. [PMID: 34407270 DOI: 10.1111/tid.13716] [Reference Citation Analysis]
17 Kohut TJ, Barandiaran JF, Keating BJ. Genomics and Liver Transplantation: Genomic Biomarkers for the Diagnosis of Acute Cellular Rejection. Liver Transpl 2020;26:1337-50. [DOI: 10.1002/lt.25812] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Kenig A, Kolben Y, Asleh R, Amir O, Ilan Y. Improving Diuretic Response in Heart Failure by Implementing a Patient-Tailored Variability and Chronotherapy-Guided Algorithm. Front Cardiovasc Med 2021;8:695547. [PMID: 34458334 DOI: 10.3389/fcvm.2021.695547] [Reference Citation Analysis]
19 Süsal C, Aykut G, Morath C, Fichtner A, Unterrainer C, Scherer S, Tran TH, Mehrabi A, Zeier M, Tönshoff B. Relevance of donor-specific antibody monitoring after kidney transplantation: Findings from the Collaborative Transplant Study and the Heidelberg Transplant Center. HLA 2019;94 Suppl 2:11-5. [PMID: 31403240 DOI: 10.1111/tan.13665] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
20 Kuypers DRJ. Intrapatient Variability of Tacrolimus Exposure in Solid Organ Transplantation: A Novel Marker for Clinical Outcome. Clin Pharmacol Ther 2020;107:347-58. [PMID: 31449663 DOI: 10.1002/cpt.1618] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 10.3] [Reference Citation Analysis]
21 Ishay Y, Potruch A, Schwartz A, Berg M, Jamil K, Agus S, Ilan Y. A digital health platform for assisting the diagnosis and monitoring of COVID-19 progression: An adjuvant approach for augmenting the antiviral response and mitigating the immune-mediated target organ damage. Biomed Pharmacother 2021;143:112228. [PMID: 34649354 DOI: 10.1016/j.biopha.2021.112228] [Reference Citation Analysis]
22 Dumortier J, Besch C, Moga L, Coilly A, Conti F, Corpechot C, Bello AD, Faitot F, Francoz C, Hilleret MN, Houssel-Debry P, Jezequel C, Lavayssière L, Neau-Cransac M, Erard-Poinsot D, de Lédinghen V, Bourlière M, Bureau C, Ganne-Carrié N. NON-INVASIVE DIAGNOSIS AND FOLLOW-UP IN LIVER TRANSPLANTATION. Clin Res Hepatol Gastroenterol 2021;:101774. [PMID: 34332131 DOI: 10.1016/j.clinre.2021.101774] [Reference Citation Analysis]
23 Deutsch-Link S, Weinrieb RM, Jones LS, Solga SF, Weinberg EM, Serper M. Prior Relapse, Ongoing Alcohol Consumption, and Failure to Engage in Treatment Predict Alcohol Relapse After Liver Transplantation. Dig Dis Sci 2020;65:2089-103. [PMID: 31707529 DOI: 10.1007/s10620-019-05937-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
24 Wozniak LJ, Venick RS. Donor-specific antibodies following liver and intestinal transplantation: Clinical significance, pathogenesis and recommendations. International Reviews of Immunology 2019;38:106-17. [DOI: 10.1080/08830185.2019.1630404] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
25 Kim SC, Foley DP. Donor-specific antibodies in liver transplantation: challenges in diagnosis and determining clinical impact. Curr Opin Organ Transplant 2020;25:549-54. [PMID: 33105198 DOI: 10.1097/MOT.0000000000000825] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Deutsch-Link S, Weinberg EM, Bittermann T, McDougal M, Dhariwal A, Jones LS, Weinrieb RM, Banerjee AG, Addis S, Serper M. The Stanford Integrated Psychosocial Assessment for Transplant Is Associated With Outcomes Before and After Liver Transplantation. Liver Transpl 2021;27:652-67. [PMID: 33320417 DOI: 10.1002/lt.25975] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
27 Ilan Y. Second-Generation Digital Health Platforms: Placing the Patient at the Center and Focusing on Clinical Outcomes. Front Digit Health 2020;2:569178. [DOI: 10.3389/fdgth.2020.569178] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
28 Coste G, Lemaitre F. The Role of Intra-Patient Variability of Tacrolimus Drug Concentrations in Solid Organ Transplantation: A Focus on Liver, Heart, Lung and Pancreas. Pharmaceutics 2022;14:379. [DOI: 10.3390/pharmaceutics14020379] [Reference Citation Analysis]
29 Khoury T, Ilan Y. Introducing Patterns of Variability for Overcoming Compensatory Adaptation of the Immune System to Immunomodulatory Agents: A Novel Method for Improving Clinical Response to Anti-TNF Therapies. Front Immunol 2019;10:2726. [PMID: 31824506 DOI: 10.3389/fimmu.2019.02726] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
30 Larpparisuth N, Pongnatcha T, Panprom P, Promraj R, Premasathian N, Vongwiwatana A. High Intrapatient Variability in Tacrolimus Exposure Calculated Over a Long Period Is Associated With De Novo Donor-Specific Antibody Development and/or Late Rejection in Thai Kidney Transplant Patients Receiving Concomitant CYP3A4/5 Inhibitors. Ther Drug Monit 2021;43:624-9. [PMID: 33278239 DOI: 10.1097/FTD.0000000000000850] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Fujiyama N, Satoh S, Saito M, Numakura K, Inoue T, Yamamoto R, Saito T, Nara T, Kanda S, Narita S, Kagaya H, Miura M, Habuchi T. Association of immunosuppressive agents and cytomegalovirus infection with de novo donor-specific antibody development within 1 year after renal transplantation. Int Immunopharmacol 2019;76:105881. [PMID: 31520989 DOI: 10.1016/j.intimp.2019.105881] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
32 Ilan Y, Spigelman Z. Establishing patient-tailored variability-based paradigms for anti-cancer therapy: Using the inherent trajectories which underlie cancer for overcoming drug resistance. Cancer Treatment and Research Communications 2020;25:100240. [DOI: 10.1016/j.ctarc.2020.100240] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
33 De Nicolò A, Pinon M, Palermiti A, Nonnato A, Manca A, Mula J, Catalano S, Tandoi F, Romagnoli R, D'Avolio A, Calvo PL. Monitoring Tacrolimus Concentrations in Whole Blood and Peripheral Blood Mononuclear Cells: Inter- and Intra-Patient Variability in a Cohort of Pediatric Patients. Front Pharmacol 2021;12:750433. [PMID: 34803692 DOI: 10.3389/fphar.2021.750433] [Reference Citation Analysis]
34 Del Bello A, Gaible C, Longlune N, Hebral AL, Esposito L, Gandia P, Kamar N. Tacrolimus Intrapatient Variability After Switching From Immediate or Prolonged-Release to Extended-Release Formulation, After an Organ Transplantation. Front Pharmacol 2021;12:602764. [PMID: 34690747 DOI: 10.3389/fphar.2021.602764] [Reference Citation Analysis]
35 Mendoza Rojas A, Hesselink DA, van Besouw NM, Baan CC, van Gelder T. Impact of low tacrolimus exposure and high tacrolimus intra-patient variability on the development of de novo anti-HLA donor-specific antibodies in kidney transplant recipients. Expert Rev Clin Immunol 2019;15:1323-31. [PMID: 31721605 DOI: 10.1080/1744666X.2020.1693263] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]